DENTSPLY SIRONA Inc. $XRAY Shares Purchased by Blue Trust Inc.

Blue Trust Inc. boosted its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAYFree Report) by 15.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,499 shares of the medical instruments supplier’s stock after purchasing an additional 1,945 shares during the quarter. Blue Trust Inc.’s holdings in DENTSPLY SIRONA were worth $230,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in DENTSPLY SIRONA in the 1st quarter valued at $25,000. Brooklyn Investment Group purchased a new stake in DENTSPLY SIRONA in the 1st quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA in the 1st quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its holdings in DENTSPLY SIRONA by 8,003.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,269 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 2,241 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in DENTSPLY SIRONA by 160.2% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 2,805 shares of the medical instruments supplier’s stock valued at $45,000 after buying an additional 1,727 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $12.47 on Wednesday. The business has a 50-day moving average of $13.42 and a 200 day moving average of $14.56. DENTSPLY SIRONA Inc. has a 12 month low of $11.69 and a 12 month high of $24.93. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of -2.63, a price-to-earnings-growth ratio of 0.76 and a beta of 0.96. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11.

DENTSPLY SIRONA (NASDAQ:XRAYGet Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The company had revenue of $936.00 million during the quarter, compared to analysts’ expectations of $929.67 million. During the same period last year, the business posted $0.49 EPS. DENTSPLY SIRONA’s revenue for the quarter was down 4.9% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. As a group, sell-side analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 10th. Shareholders of record on Friday, September 26th were given a $0.16 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $0.64 dividend on an annualized basis and a yield of 5.1%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is currently -13.50%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on XRAY. Stifel Nicolaus dropped their target price on DENTSPLY SIRONA from $19.00 to $17.00 and set a “hold” rating for the company in a report on Friday, August 8th. Barrington Research lowered their price target on DENTSPLY SIRONA from $21.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Wall Street Zen upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday, September 26th. Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a report on Friday, September 26th. Finally, UBS Group lowered their price target on DENTSPLY SIRONA from $25.00 to $24.00 and set a “buy” rating for the company in a report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $18.00.

Check Out Our Latest Research Report on DENTSPLY SIRONA

DENTSPLY SIRONA Profile

(Free Report)

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

Featured Stories

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.